RD: Interchangeable cheaper insulin hits U.S. shelves and more + your exclusive access to the Reframe Community

Reframe Daily is where Christin Chong (neuroscience PhD, chaplain, healthtech strategy consultant) curates optimistic and credible healthtech news so you don’t have to.

Christin’s note: As an early Reframe Daily subscriber, you are welcomed to Reframe community where you can receive personalized healthcare news and support!

Please fill out this quick 2 question form here and you’ll get the link to join right away: https://forms.gle/tN3oabFTsDF21VnS8

Today in one sentence: The FDA cleared a cheaper swap-in insulin called Kirsty; everyday diabetes shots semaglutide and tirzepatide also lowered dementia and stroke risk; pairing PTSD therapy with drinking help slashed symptoms and alcohol use in women; a smart computer tool in hospitals cut unneeded scans; and a lab-made antibody saved monkeys from deadly yellow fever, hinting at quick protection for people.

Good news: Pharmacies can soon swap in Kirsty—the first look-alike, switch-able version of fast-acting NovoLog insulin—so people with diabetes should pay less and get refills more easily.

FDA Approves Kirsty as First Interchangeable Insulin Aspart Biosimilar

Market readiness: 🙂🙂🙂🙂🙂 (already FDA-approved; pens and vials ship within weeks)

Good news: A study of 60,860 adults found that the diabetes shots semaglutide and tirzepatide also lower chances of dementia by 37 percent and stroke by 19 percent—extra protection doctors can tell patients about right now.

Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity

Market readiness: 🙂🙂🙂🙂🙂 (these GLP-1 injectables are already on U.S. pharmacy shelves)

Good news: Mixing proven PTSD therapy with alcohol-use counseling in one 12-week program cut women’s PTSD symptoms and heavy-drinking days in half, so clinics can start using the combo without new meds or devices.

Concurrent Treatment of Post-Traumatic Stress Disorder and Alcohol Use Disorder in Women: A Randomized Clinical Trial

Market readiness: 🙂🙂🙂🙂🙂 (both therapies are standard and can be combined immediately)

Good news: Hospitals that turned on an electronic decision-support tool ordered fewer unnecessary scans and got the right images faster in a cluster trial across many sites—software most U.S. EHRs can plug in with light IT work.

Evaluation of a Clinical Decision Support System for Imaging Requests: Cluster Randomized Clinical Trial

Market readiness: 🙂🙂🙂🙂 (already compatible with common EHR platforms; needs local rollout and staff training)

Good news: A single lab-made antibody kept monkeys from dying of yellow-fever virus—and even saved some after infection—hinting at a fast back-up if vaccines can’t be given during outbreaks.

Prophylactic and Therapeutic Neutralizing Monoclonal Antibody Treatment Prevents Lethal Yellow-Fever Infection

Market readiness: 🙂 (animal success only; human safety trials still to be launched)

Thank you for taking the time to reframe! Take care of yourself and your loved ones.